The AML Content Hub Channel

Expert Explores Potential Role of Doublets and Triplets in IDH1-Mutant Acute Myeloid Leukemia

Courtney D. DiNardo, MD, clinical researcher in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses how potential doublet and triplet combination treatments may work in patients with IDH1-mutated acute myeloid leukemia (AML). DiNardo explains that the next step is determining the proper regimens that yield the best results for patients.

Click here to learn more.

More in AML Content Hub

► 1:24

New Strategies for Cytopenia Management in MDS

AML Content Hub

In an interview conducted during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes, Uwe Platzbecker, MD, Director of the Medical Clinic I at the...

► 1:22

The Immunological Impact of TP53 in Patients With MDS

AML Content Hub

In an interview conducted during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes, Shahram Kordasti, MD, PhD, King's College London, London, UK, discusses TP53...

► 3:56

The Impact of Genetics on Treatment for Patients With MDS

AML Content Hub

During the virtual European Hematology Association (EHA) Congress 2021, Valeria Santini, MD, an associate professor of hematology at the University of Florence, in Florence, Italy, discusses the genomic landscape of...

► 2:36

Earlier AML Detection

AML Content Hub

In an interview conducted at the 2021 ASCO Annual Meeting, Chris Hourigan, MD, DPhil, National Institutes of Health, Bethesda, Maryland, discusses earlier detection of AML. Among patients who initially respond...